Moderna forecasts $18.4 billion revenue for 2021 PUBLISHED BY
$18.4 billion in 2021 from its Covid-19 vaccine deals.
Moderna, before it came up with the vaccine for the coronavirus, was going in losses. The company’s forecast of $18 billion-plus is quite higher than what Wall Street analysts have predicted for it. They put the revenue at $11.2 billion. Moderna reported revenue of $571 million in the fourth quarter, largely from the US government grants and sales of its Covid-19 vaccine.
Moderna is optimistic about its performance due to its discussions with governments about more vaccine orders for 2021 and 2022.
The company suffered a net loss of $272 million. It expects $350 million to $400million in capital expenditure in 2021. Total revenue was $803 million for the year ended December 31, 2020. Net loss was $747 million for the year, compared to $514 million for the year ended December 31, 2019.
Coronavirus: Pfizer vaccine 94% effective, confirms mass real-world study
The research involved about 12 lakh people in Israel. File photo: Syringes prepared for the Pfizer-BioNTech coronavirus vaccine. | Hannibal Hanschke/Reuters
A big real-world test of Pfizer and BioNTech’s coronavirus vaccine has shown that the jab is 94% effective. The results of the study, which involved about 12 lakh people in Israel, were published in the
New England Journal of Medicine on Wednesday
.
The results are very close to the vaccine’s phase 3 clinical trials last year, which found that two doses were 95% effective.
The study estimated the vaccine to be 57% effective against the infection two to three weeks after the first dose and 94% effective a week or longer after the second dose. It involved 6 lakh inoculated people and a similarly-sized control group of unvaccinated participants.
New drugs identified as possible tools to fight COVID-19
There will probably never be a perfect treatment to cure COVID-19 but the right medications for the right patients can save lives.
ByMichael Greshko
Email
After grappling with the virus SARS-CoV-2 for more than a year, clinics still face the same reality they did months ago: There are no quick and easy fixes for treating COVID-19.
“I’m not surprised that we don’t have a magic bullet,” says the Cleveland Clinic’s Adarsh Bhimraj, one of the lead authors of the Infectious Diseases Society of America’s (IDSA) COVID-19 treatment guidelines. “None of the respiratory viral infections that we’ve known for all these decades and centuries has a magic bullet.”
Moderna Inc said on Wednesday it is working with U.S. government scientists to study an experimental booster shot that targets a concerning new variant of the…